Abstract
Background: We assessed the frequency and severity of hypoglycemia in type 2 diabetes mellitus patients treated with sulfonylurea monotherapy or sulfonylurea+metformin. Methods: We conducted a retrospective, observational, cross-sectional study in 2011 and 2012 including patients with type 2 diabetes mellitus aged ≥30 years who were treated with ≥6 months of sulfonylurea monotherapy or sulfonylurea+metformin at 20 university-affiliated hospitals in Korea. At enrollment, glycated hemoglobin (HbA1c) was assessed; participants completed self-reported questionnaires describing hypoglycemia incidents over the past 6 months. A review of medical records up to 12 months before enrollment provided data on demographics, disease history, comorbidities, laboratory results, and drug usage. Results: Of 726 enrolled patients, 719 were included (55.6% male); 31.7% and 68.3% were on sulfonylurea monotherapy and sulfonylurea+metformin, respectively. Mean±standard deviation age was 65.9±10.0 years; mean HbA1c level was 7.0%±1.0%; 77.8% of patients had hypertension (89.4% used antihypertensive medication); 60.5% had lipid disorders (72.5% used lipid-lowering medication); and 52.0% had one or more micro- or macrovascular diseases. Among patients with A1c measurement (n=717), 56.4% achieved therapeutic goals (HbA1c < 7.0%); 42.4% (305/719) experienced hypoglycemia within 6 months of enrollment; and 38.8%, 12.9%, 12.7%, and 3.9% of patients experienced mild, moderate, severe, and very severe hypoglycemia symptoms, respectively. Several reported hypoglycemia frequency as 1-2 times over the last 6 months. The mean number of very severe hypoglycemia episodes was 3.5±5.5. Conclusion: Among type 2 diabetes mellitus patients treated with sulfonylurea-based regimens, glycemic levels were relatively well controlled but hypoglycemia remained a prevalent side effect.
| Original language | English |
|---|---|
| Pages (from-to) | 212-219 |
| Number of pages | 8 |
| Journal | Korean Journal of Family Medicine |
| Volume | 40 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2019 Jul 1 |
Fingerprint
Keywords
- Glycated hemoglobin A
- Hypoglycemia
- Metformin
- Sulfonylurea
- Type 2 diabetes mellitus
ASJC Scopus subject areas
- Family Practice
Cite this
Frequency and severity of hypoglycemia in type 2 diabetes mellitus patients treated with a sulfonylurea-based regimen at university-affiliated hospitals in Korea : The naturalistic evaluation of hypoglycemic events in diabetic subjects study. / Kim, Yon Su; Cho, Be Long; Kim, Woo Sik; Kim, Sang Hyun; Jung, In Hyeon; Sin, Won Yong; Choi, Dong Hoon; Lee, Sang Jae; Lim, Chun Soo; Kang, Kyung Pyo; Yu, Byung Yeon; Jeung, Wonju; Park, Chang Gyu.
In: Korean Journal of Family Medicine, Vol. 40, No. 4, 01.07.2019, p. 212-219.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Frequency and severity of hypoglycemia in type 2 diabetes mellitus patients treated with a sulfonylurea-based regimen at university-affiliated hospitals in Korea
T2 - The naturalistic evaluation of hypoglycemic events in diabetic subjects study
AU - Kim, Yon Su
AU - Cho, Be Long
AU - Kim, Woo Sik
AU - Kim, Sang Hyun
AU - Jung, In Hyeon
AU - Sin, Won Yong
AU - Choi, Dong Hoon
AU - Lee, Sang Jae
AU - Lim, Chun Soo
AU - Kang, Kyung Pyo
AU - Yu, Byung Yeon
AU - Jeung, Wonju
AU - Park, Chang Gyu
PY - 2019/7/1
Y1 - 2019/7/1
N2 - Background: We assessed the frequency and severity of hypoglycemia in type 2 diabetes mellitus patients treated with sulfonylurea monotherapy or sulfonylurea+metformin. Methods: We conducted a retrospective, observational, cross-sectional study in 2011 and 2012 including patients with type 2 diabetes mellitus aged ≥30 years who were treated with ≥6 months of sulfonylurea monotherapy or sulfonylurea+metformin at 20 university-affiliated hospitals in Korea. At enrollment, glycated hemoglobin (HbA1c) was assessed; participants completed self-reported questionnaires describing hypoglycemia incidents over the past 6 months. A review of medical records up to 12 months before enrollment provided data on demographics, disease history, comorbidities, laboratory results, and drug usage. Results: Of 726 enrolled patients, 719 were included (55.6% male); 31.7% and 68.3% were on sulfonylurea monotherapy and sulfonylurea+metformin, respectively. Mean±standard deviation age was 65.9±10.0 years; mean HbA1c level was 7.0%±1.0%; 77.8% of patients had hypertension (89.4% used antihypertensive medication); 60.5% had lipid disorders (72.5% used lipid-lowering medication); and 52.0% had one or more micro- or macrovascular diseases. Among patients with A1c measurement (n=717), 56.4% achieved therapeutic goals (HbA1c < 7.0%); 42.4% (305/719) experienced hypoglycemia within 6 months of enrollment; and 38.8%, 12.9%, 12.7%, and 3.9% of patients experienced mild, moderate, severe, and very severe hypoglycemia symptoms, respectively. Several reported hypoglycemia frequency as 1-2 times over the last 6 months. The mean number of very severe hypoglycemia episodes was 3.5±5.5. Conclusion: Among type 2 diabetes mellitus patients treated with sulfonylurea-based regimens, glycemic levels were relatively well controlled but hypoglycemia remained a prevalent side effect.
AB - Background: We assessed the frequency and severity of hypoglycemia in type 2 diabetes mellitus patients treated with sulfonylurea monotherapy or sulfonylurea+metformin. Methods: We conducted a retrospective, observational, cross-sectional study in 2011 and 2012 including patients with type 2 diabetes mellitus aged ≥30 years who were treated with ≥6 months of sulfonylurea monotherapy or sulfonylurea+metformin at 20 university-affiliated hospitals in Korea. At enrollment, glycated hemoglobin (HbA1c) was assessed; participants completed self-reported questionnaires describing hypoglycemia incidents over the past 6 months. A review of medical records up to 12 months before enrollment provided data on demographics, disease history, comorbidities, laboratory results, and drug usage. Results: Of 726 enrolled patients, 719 were included (55.6% male); 31.7% and 68.3% were on sulfonylurea monotherapy and sulfonylurea+metformin, respectively. Mean±standard deviation age was 65.9±10.0 years; mean HbA1c level was 7.0%±1.0%; 77.8% of patients had hypertension (89.4% used antihypertensive medication); 60.5% had lipid disorders (72.5% used lipid-lowering medication); and 52.0% had one or more micro- or macrovascular diseases. Among patients with A1c measurement (n=717), 56.4% achieved therapeutic goals (HbA1c < 7.0%); 42.4% (305/719) experienced hypoglycemia within 6 months of enrollment; and 38.8%, 12.9%, 12.7%, and 3.9% of patients experienced mild, moderate, severe, and very severe hypoglycemia symptoms, respectively. Several reported hypoglycemia frequency as 1-2 times over the last 6 months. The mean number of very severe hypoglycemia episodes was 3.5±5.5. Conclusion: Among type 2 diabetes mellitus patients treated with sulfonylurea-based regimens, glycemic levels were relatively well controlled but hypoglycemia remained a prevalent side effect.
KW - Glycated hemoglobin A
KW - Hypoglycemia
KW - Metformin
KW - Sulfonylurea
KW - Type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=85069763308&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069763308&partnerID=8YFLogxK
U2 - 10.4082/kjfm.18.0051
DO - 10.4082/kjfm.18.0051
M3 - Article
AN - SCOPUS:85069763308
VL - 40
SP - 212
EP - 219
JO - Korean Journal of Family Medicine
JF - Korean Journal of Family Medicine
SN - 2005-6443
IS - 4
ER -